Iparomlimab/Tuvonralimab in Mucosal Melanoma: NCT07347444 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Not yet recruiting
Recruitment status
48
Planned enrollment
2028-12-01
Primary-completion proxy
Executive view
NCT07347444 evaluates Iparomlimab/Tuvonralimab in Mucosal Melanoma. The disclosed sponsor is Fudan University, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Objective response rate (ORR), assessed over up to 2 years.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07347444 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Mucosal Melanoma landscape. Drug & Asset MCP drug_fetch was queried for Iparomlimab/Tuvonralimab, while Company & Deal Intelligence MCP organization_fetch was queried for Fudan University.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07347444 | Iparomlimab/Tuvonralimab | Phase 2 / Not yet recruiting | Fudan University | China | Objective response rate (ORR) up to 2 years | 2028-12-01 |
| NCT07504796 | Ipilimumab | Phase 2 / Recruiting | NYU Langone Health | United States | Progression Free Survival rate in patients randomized in Cohort B Month 6 | 2029-05-01 |
| NCT07501117 | Ipilimumab | Phase 1 / Recruiting | Herlev Hospital | Denmark | Number of patients experiencing CTCAE grade ≥ 3 AEs and the occurrence of any treatment related adverse event (AEs) Until 6 months post treatment | 2029-06-01 |
| NCT07476326 | Nivolumab | Phase 1 / Not yet recruiting | Biocon Biologics Uk Plc | Romania, Ukraine, Turkey, Brazil, South Africa, Moldova, United States, Serbia, Chile, Spain | Area Under the Concentration-Time Curve from Time 0 (Day 1) To Day 29 After the First Dose (AUC0-28days) of Bmab 1700 a… Week 0 through Week 4 | 2027-08-16 |
| NCT07475572 | Pembrolizumab biosimilar(Alvotech) | Phase 1 / Recruiting | Alvotech Swiss AG | Ukraine | To demonstrate PK similarity of AVT32-DRL_PB versus Keytruda (pembrolizumab) Cycle 1 (each cycle is 21 days) | 2027-10-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07347444 is a Phase 2, not yet recruiting study with 48 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Objective response rate (ORR)” over “up to 2 years.” The retrieved endpoint description is: Defined as the percentage of participants in the analysis population who experienced a Complete Response or a Partial Response and was assessed using RECIST 1.1 based on investigator evaluation..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 48 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Mucosal Melanoma. These records do not establish direct evidence for NCT07347444 unless the registration number matches.
A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma
Phase 2; n=30; AE(Grade 3 and higher) = 50.0 % Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/41732954/
A Phase II Study to Evaluate the Safety and Efficacy of Rigosertib (ON 01910) Plus Pembrolizumab in Patients With Metastatic Melanoma Refractory to Immune Checkpoint Blockade
Phase 2; n=7; ORR = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05764395
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to PD-1…
Phase 2; n=23; CR = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04796194
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Iparomlimab/Tuvonralimab is indexed as Bispecific antibody with CTLA4 x PD-1 biology and a global stage of Approved. The asset profile lists Qilu Pharmaceutical Co., Ltd. as an originator or developer.
Fudan University is indexed in China with the website http://www.fudan.edu.cn. Fudan University is an institution of higher education in China. The record lists 344 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Iparomlimab/Tuvonralimab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07347444
Protocol source: https://clinicaltrials.gov/study/NCT07347444
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.
Iparomlimab/Tuvonralimab in Mucosal Melanoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Objective response rate (ORR) and 2028-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
